BNP Paribas Asset Management
IBRX icon

BNP Paribas Asset Management’s ImmunityBio IBRX Stock Holding History

BNP Paribas Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46K Sell
5,259
-476
-8% -$3.6K ﹤0.01% 1793
2026
Q1 		$44K Buy
5,735
+1,905
+50% +$13K ﹤0.01% 1791
2025
Q4 		$8K Buy
3,830
+1,335
+54% +$3.02K ﹤0.01% 2212
2025
Q3 		$6K Buy
2,495
+473
+23% +$1.22K ﹤0.01% 1772
2025
Q2 		$5K Buy
+2,022
New +$5.44K ﹤0.01% 2009

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Asset Management's IBRX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its ImmunityBio (IBRX) stake by 8.3% in Q2 2026, selling an estimated $3.6K and leaving 5,259 shares worth $46K. The position accounts for ﹤0.01% of the portfolio, ranked #1793.

BNP Paribas Asset Management first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • BNP Paribas Asset Management held 5,259 shares of ImmunityBio worth $46K as of Q2 2026.
  • BNP Paribas Asset Management sold 476 ImmunityBio shares in Q2 2026, an estimated $3.6K.
  • ImmunityBio made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1793 holding.
  • BNP Paribas Asset Management first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.